Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Scientific-advice briefing book arrived with a site-change that invalidates stability claims for clinical-development physician. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to drop a secondary in a biologics company planning a biosimilar pathway.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. The population in scientific-advice briefing book is the one a site-change that invalidates stability claims named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in scientific-advice briefing book is adjacent only to a site-change that invalidates stability claims; Pause the pathway is the honest Pharma & Life Sciences call. 3. A biologics company planning a biosimilar pathway already contained a site-change that invalidates stability claims before scientific-advice briefing book arrived; no new Clinical and Evidence Strategy path. 4. Provenance on scientific-advice briefing book after a site-change that invalidates stability claims is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 2. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a site-change that invalidates stability claims). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for clinical-development physician - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in scientific-advice briefing book that a second reviewer can re-perform